Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs041250111) titled 'Biweekly Combination therapy of Urothelial carcinoma with Regimen Evaluation' on Oct. 7.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Izumi Kouji
Condition:
Patients with unresectable urothelial carcinoma
transitional cell carcinoma
Carcinoma, Transitional Cell
Intervention:
One treatment cycle is defined as 42 days. Enfortumab vedotin will be administered at 1.25 mg/kg on Days 1, 15, and 29, and pembrolizumab at 200 mg/body on Days 1 and 22. For patients deemed by the physician to be at lo...